Scholar Rock Holding Corporation (SRRK) News
Filter SRRK News Items
SRRK News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SRRK News Highlights
- SRRK's 30 day story count now stands at 4.
- Over the past 16 days, the trend for SRRK's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- ROCK are the most mentioned tickers in articles about SRRK.
Latest SRRK News From Around the Web
Below are the latest news stories about SCHOLAR ROCK HOLDING CORP that investors may wish to consider to help them evaluate SRRK as an investment opportunity.
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., March 15, 2023--Scholar Rock (NASDAQ: SRRK; "The Company"), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 26,250 shares of its common stock to 1 newly hired employee, consisting of inducement stock options to purchase an aggregate of 15,000 shares of common stock and inducement rest |
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business ProgressCAMBRIDGE, Mass., March 07, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results and corporate updates for the full year ended December 31, 2022. |
Scholar Rock to Present 24-Month Data from the Phase 2 TOPAZ trial at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceCAMBRIDGE, Mass., March 01, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced it will present data from its Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24 months of treatment with apitegromab, an investigational selective inhibitor of the activation of myostatin for spinal muscular atrophy (SMA). An analysis of quali |
Scholar Rock to Present at the Cowen 43rd Annual Health Care ConferenceCAMBRIDGE, Mass., February 27, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the Cowen 43rd Annual Health Care Conference on Tuesday, March 7, 2023, at 12:50 p.m. ET. |
Shareholders in Scholar Rock Holding (NASDAQ:SRRK) have lost 43%, as stock drops 13% this past weekWhile it may not be enough for some shareholders, we think it is good to see the Scholar Rock Holding Corporation... |
Scholar Rock Appoints Tracey M. Sacco as Chief Commercial OfficerCAMBRIDGE, Mass., February 06, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Tracey M. Sacco as Chief Commercial Officer. Ms. Sacco brings extensive biopharmaceutical industry experience, including product launch and global commercial strategy. At Scholar Rock, she will build and lead all commercial functions, including s |
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023CAMBRIDGE, Mass., January 09, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming priorities for its pipeline programs in 2023. |
Scholar Rock to Present at the 41st Annual J.P. Morgan Healthcare ConferenceCAMBRIDGE, Mass., January 03, 2023--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that management will present at the J.P. Morgan 41st Annual Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. PT (4:30 p.m. ET). |
Scholar Rock Holding Third Quarter 2022 Earnings: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)Scholar Rock Holding ( NASDAQ:SRRK ) Third Quarter 2022 Results Key Financial Results Net loss: US$43.3m (loss widened... |
H.C. Wainwright Keeps Their Buy Rating on Scholar Rock Holding (SRRK)H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating on Scholar Rock Holding (SRRK - Research Report) today and set a price target of $30.00. The company's shares closed yesterday at $8.59.According to TipRanks, Y. Maldonado is ranked #6545 out of 8017 analysts.The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Scholar Rock Holding with a $30.00 average price target.See Insiders’ Hot Stocks on TipRanks >> Based on Scholar Rock Holding's latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $44 million. In comparison, last year the company earned a revenue of $4. |